3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
10
Neoplasm Metastasis
7
Melanoma
5
Neoplasms
4
Thyroid Neoplasms
3
Neurofibromatosis 1
3
Lung Neoplasms
3
Uveal Melanoma
2
Thyroid Cancer, Papillary
2
Pancreatic Neoplasms
2
Carcinoma, Hepatocellular
2
Breast Neoplasms
2
Triple Negative Breast Neoplasms
1
Thyroid Diseases
1
Thymoma
1
Solid Tumours
1
Solid Tumors
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Rectal Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Neuroma, Acoustic
1
Neurofibrosarcoma
1
Neurofibromatosis 2
1
Neurofibroma, Plexiform
1
Neuroblastoma
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Meningioma
1
Interventions
pembrolizumab
120
Cisplatin
26
Carboplatin
24
Paclitaxel
21
Docetaxel
17
lenvatinib
15
Pemetrexed
12
Fluorouracil
12
Saline Solution
11
Capecitabine
10
epacadostat
8
Oxaliplatin
7
Gemcitabine
7
Leucovorin
5
Cetuximab
5
130-nm albumin-bound paclitaxel
5
olaparib
4
enzalutamide
4
Irinotecan
4
Bevacizumab
4
Albumin-Bound Paclitaxel
4
trifluridine tipiracil drug combination
3
regorafenib
3
Prednisone
3
Dexamethasone
3
Radiotherapy
2
Ipilimumab
2
Glucose
2
Etoposide
2
Doxorubicin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Parkinson Disease 4, Autosomal Dominant Lewy Body
×
AZD 6244
×
Clear all
NCT03833427
2024-11-07
MK-5618-001
Merck Sharp & Dohme LLC
Phase 1
Terminated
32 enrolled
17 charts